Complaint
| Product Name | Lidocain e |
| CAS NO. | 137-58 6 |
| Appearance | White powder |
| Purity | 99% |
| Melting point | 66-69 °C (dec.) (lit.) |
| Boiling point | 372.7°C(Predicted) |
| Density | 0.9944 g/mL at 25 °C(lit.) |
| Application | Raw materials; medical local anesthesia; health care raw materials; anesthetics and auxiliary drugs |
| Chemical Structure | |
| Usage | Lidocain e is a local anesthetic, also known as Xerocaine. It has replaced procain e in recent years and is widely used in cosmetic plastic surgery for local infiltration anesthesia. It inhibits the sodium ion channels in the nerve cell membrane. Cut off nerve excitation and conduction. Its fat-solubility and protein binding rate are higher than procain e, its ability to penetrate cells is strong, its effect is fast, its effect is long, and its strength is 4 times that of procain e. It is clinically used in infiltration anesthesia, epidural anesthesia, surface anesthesia (including mucosal anesthesia during thoracoscopy or abdominal surgery) and nerve block. In order to prolong the time of anesthesia and reduce the side effects such as lidocain e poisoning, can be added to the anesthetic. Lidocain e can also be used to treat ventricular premature beats, ventricular tachycardia, digitalis poisoning, cardiac surgery and cardiac catheter-induced ventricular arrhythmias after acute myocardial infarction, including ventricular premature beats, ventricular tachycardia and Ventricular fibrillation. Secondly, it is also used for status epilepticus for those who are ineffective with other anticonvulsants and for local or intraspinal anesthesia. But it is usually not effective for supraventricular arrhythmia. |
| Storage | Normal Temperature |
Items | Specifications |
| CAS | 73-78-9 |
| Boiling Point | 350.8ºC at 760 mmHg |
|---|---|
| Melting Point | 80-82°C |
| Molecular Formula | C14H23ClN2O |
| Molecular Weight | 270.798 |
| Flash Point | 166ºC |
| Exact Mass | 270.149902 |
| PSA | 32.34000 |
| LogP | 3.45870 |
| Storage condition | Refrigerator |
| Detailed Photos | Lidoca hydrochloride is metabolized rapidly by the liver, and metabolites and unchanged drug are excreted by the kidneys. Biotransformation includes oxidative N-dealkylation, ring hydroxylation, cleavage of the amide linkage, and conjugation. N-dealkylation, a major pathway of biotransformation, yields the metabolites monoethylglycinexylidide and glycinexylidide. The pharmacological/toxicological actions of these metabolites are similar to, but less potent than, those of Lidoca hydrochloride. Approximately 90% of Lidoca hydrochloride administered is excreted in the form of various metabolites, and less than 10% is excreted unchanged. The primary metabolite in urine is a conjugate of 4-hydroxy-2,6-dimethylaniline. |
| Function: | Function: 1. Lidoca, xylocaine, or lignocaine is a common local anesthetic and class-1b antiarrhythmic drug. Lidoca is used topically to relieve itching, burning, and pain from skin inflammations, injected as a dental anesthetic, or as a local anesthetic for minor surgery. 2.It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic healthcare system. 3. Lidoca is the most important class-1b antiarrhythmic drug; it is used intravenously for the treatment of ventricular arrhythmias (for acute myocardial infarction, digoxine poisoning, cardioversion, or cardiac catheterization) if amiodarone is not available or contraindicated. 4. Lidoca ophylactic administration is no longer recommended for acute cardiac infarction; the overall benefit of this measure is not convincing. |
| Lidoca Hcl Description | 1.Lidoca hcl is a local anesthetic and antiarrhythmic drug. It is clinically used for infiltration anesthesia, epidural anesthesia, surface anesthesia (including in the thoracoscopy or abdominal surgery for mucosal anesthesia) and nerve conduction block. 2.Lidoca hcl is an amide local anesthetic. With the dose increased, the role or toxicity increased, there is an anti-convulsive effect with sub-poisoning plasma concentration; Blood concentration of more than 5μg • ml-1 can occur convulsions. 3.Lidoca hcl in low doses can promote outflow of K+ in cardiomyocytes, reduce myocardial autonomy, and has antiarrhythmic effects. Increased plasma concentration may cause slowing of heart conduction, atrioventricular block, inhibition of myocardial contractility and decreased cardiac output. |
Q1: How to confirm the Product Quality before placing orders?
